Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2022-11-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司关于获得阿加曲班注射液药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from the National Medical Products Administration (国家药品监督管理局). It details the drug's specifications, approval, and potential impact on the company. The document is short (1133 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or other report content. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval.
2022-11-07 Chinese
第八届监事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at the seventh meeting of the eighth Supervisory Board of Beijing Shuanglu Pharmaceutical Co., Ltd. It details the approval of a related-party transaction involving the acquisition of a subsidiary's equity. The document includes meeting attendance, voting results, and compliance with company law and listing rules. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is an official announcement of a board/management decision related to corporate governance and transactions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on a board resolution, not a full report or regulatory filing.
2022-10-31 Chinese
第八届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the seventh meeting of the eighth board of directors of Beijing Shuanglu Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and related party transaction approval. There is no indication of a full annual or interim report, audit report, or earnings release. The content focuses on board decisions and management actions, specifically about a share acquisition and related party transaction. This fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Therefore, the classification is MANG with high confidence.
2022-10-31 Chinese
北京双鹭药业股份有限公司独立董事关于公司受让控股子公司新乡双鹭药业有限公司股权暨关联交易的独立意见
Regulatory Filings Classification · 90% confidence The document is an independent director's opinion on a related-party transaction involving the company acquiring additional equity in a subsidiary. It discusses the transaction details, compliance with regulatory rules, and the impact on the company and shareholders. It is not a full financial report, earnings release, or regulatory filing but a specific opinion related to a corporate transaction and governance. This fits best under Regulatory Filings (RNS) as it is a compliance-related announcement that does not fit other categories like M&A or Board/Management changes directly, nor is it a full audit or financial report.
2022-10-31 Chinese
北京双鹭药业股份有限公司关于受让控股子公司股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's acquisition of a controlling stake in its subsidiary and the related party transaction details. It includes information about the transaction, parties involved, financial data of the related companies, pricing policy, and independent directors' opinions. The document is a formal announcement of a capital transaction involving share acquisition and related party dealings. It does not contain comprehensive financial statements or detailed financial performance reports typical of Annual Reports (10-K) or Interim Reports (IR). It is not a call transcript, earnings release, or management report. The content fits best under Capital/Financing Update (CAP) as it details a financing-related transaction (acquisition of subsidiary shares) and related party transaction disclosures. The document length (5319 characters) and detailed transaction information support this classification with high confidence.
2022-10-31 Chinese
2022年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年第三季度报告' which translates to '2022 Third Quarter Report'. It contains detailed financial data including income, net profit, cash flow, earnings per share, and balance sheet items as of September 30, 2022. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters) and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2022
2022-10-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.